April 2014
Volume 55, Issue 13
Free
ARVO Annual Meeting Abstract  |   April 2014
Baseline Visual Field Damage as a Predictor of Faster Rates of Visual Field Progression in the Low-pressure Glaucoma Treatment Study
Author Affiliations & Notes
  • Jessica Eva Chan
    Ophthalmology, New York University School of Medicine, New York, NY
  • Gustavo V De Moraes
    Ophthalmology, New York University School of Medicine, New York, NY
    Einhorn Clinical Research Center, New York Eye and Ear Infirmary, New York, NY
  • Robert N Weinreb
    Hamilton Glaucoma Center, University of California at San Diego, San Diego, CA
  • David S Greenfield
    Ophthalmology, Bascom Palmer Eye Institute, University of Miami Miller School of Medicine, Palm Beach Gardens, FL
  • Theodore Krupin
    Ophthalmology, Feinberg School of Medicine, Northwestern University, Chicago, IL
    The Chicago Center for Vision Research, Chicago, IL
  • Stuart Keith Gardiner
    Devers Eye Institute, Legacy Health, Portland, OR
  • Jeffrey M Liebmann
    Ophthalmology, New York University School of Medicine, New York, NY
    Einhorn Clinical Research Center, New York Eye and Ear Infirmary, New York, NY
  • Robert Ritch
    Einhorn Clinical Research Center, New York Eye and Ear Infirmary, New York, NY
    Ophthalmology, New York Medical College, Valhalla, NY
  • Footnotes
    Commercial Relationships Jessica Chan, None; Gustavo De Moraes, None; Robert Weinreb, None; David Greenfield, Allergan (C); Theodore Krupin, Allergan, Inc (C); Stuart Gardiner, None; Jeffrey Liebmann, Alcon, Inc (C), Allergan, Inc (C), Allergan, Inc (F), Bausch & Lomb, Inc (C), Bausch & Lomb, Inc (F), Carl Zeiss Meditech, Inc (F), Diopysis, Inc (C), Diopysis, Inc (F), Heidelberg Engineering, GmbH (C), Heidelberg Engineering, GmbH (F), Merz Pharmaceuticals, Inc (C), National institutes of Health (F), National Institutes of Health (F), New York Glaucoma Research Institute (F), Optovue, Inc (F), Quark Pharmaceuticals, Inc (F), Reichert, Inc (F), Sensimed, Inc (F), Topcon, Inc (F), Valeant Pharmaceuticals, Inc (C); Robert Ritch, None
  • Footnotes
    Support None
Investigative Ophthalmology & Visual Science April 2014, Vol.55, 5638. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Jessica Eva Chan, Gustavo V De Moraes, Robert N Weinreb, David S Greenfield, Theodore Krupin, Stuart Keith Gardiner, Jeffrey M Liebmann, Robert Ritch, Low-Pressure Glaucoma Treatment Group; Baseline Visual Field Damage as a Predictor of Faster Rates of Visual Field Progression in the Low-pressure Glaucoma Treatment Study. Invest. Ophthalmol. Vis. Sci. 2014;55(13):5638.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: To investigate whether baseline visual field (VF) damage is a predictor of faster rates of progression in the Low-pressure Glaucoma Treatment Study (LoGTS).

Methods: In this prospective, randomized, double-masked, multicenter clinical trial, patients with ≥5 VF tests during follow-up were included. To minimize a "floor effect" expected in eyes with severe VF loss on rates of VF change, only eyes with baseline MD better than -16 dB were included. Also, PSD is known to have an increasing monotonic function up to that MD cut-off value on average, which mitigates the effect of diffuse sensitivity loss on PSD values normally see after that point. Progression was determined using pointwise linear regression analysis, defined as the same 3 or more VF locations with a slope more negative than -1.0 dB/year at P <5%, on 3 consecutive examinations. Cox Proportional hazards method using a backward elimination approach was used to test whether known risk factors (age, IOP, central corneal thickness, treatment for systemic hypertension, migraine, Reynaud’s, and mean arterial ocular perfusion pressure) in addition to baseline mean deviation (MD) or pattern standard deviation (PSD) were associated with faster progression. Eyes with high PSD values at baseline were considered to have localized, deep VF loss, as opposed to diffuse loss when the MD was more negative.

Results: Timolol and brimonidine groups had similar baseline MD (P=0.67) and PSD (P=0.84). In the multivariable model that included baseline PSD, randomization to timolol (Hazard Ratio, HR=3.27, P=0.001), older age (HR=1.03, P=0.014), treatment for systemic hypertension (HR=3.13, P=0.001), increased mean ocular perfusion pressure (HR=0.82, P<0.001), and worse PSD (HR=1.09, P=0.039). The model including MD did not reveal statistical significance of this variable (P=0.79). The average sensitivity of the 4 central-most points at baseline was a significant predictor of faster progression (P<0.001).

Conclusions: In treated patients with low-pressure glaucoma, eyes with localized, deep, and central VF defects at baseline progressed faster than those with diffuse loss.

Keywords: 758 visual fields  
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×